Consumers don’t always pay more because they’re confused. Sometimes they pay more because the market has trained them to trust.
That’s the uncomfortable truth behind branded generics—the category where “generic” is technically true, but the experience …

Pharma teams are drowning in data—and still losing to competitors.
That’s the uncomfortable truth behind the “intelligence gap” many organizations quietly accept: they can see what’s happening in the market, but they don’t consistently see what’s about…

Two Systems, One Fight: How the Patent Dance and Orange Book Linkage Are Shaping the $400B Biologics War
Biologics are no longer just “the next wave” of healthcare—they’re the battleground. With the global biologics market projected to reach roughly $4…

Most pharma teams don’t lose to competitors because they lack talent. They lose because they’re late.
Late to spot an approaching patent cliff. Late to understand what’s actually expiring—and when. Late to map the regulatory path that turns “maybe” int…

Patent cliffs don’t just create pricing pressure—they create strategic openings. The question for pharma isn’t whether generics will arrive after exclusivity ends. It’s whether you’ll be ready to defend your franchise, manage your pipeline, and shape t…

AI is quietly becoming the new “KOL” in pharma—and most companies aren’t tracking it.
For years, drugmakers have mapped influence the old way: key opinion leaders, conference circuits, advisory boards, and the slow grind of peer-reviewed credibility. B…

Most pharma teams wait until the patent is already dying. That’s why they miss the money.
In drug development, timing is everything—but in licensing, timing is everything squared. The closer a product gets to patent expiry, the more value concentrates …

Drug patent expiry isn’t a single date—it’s a moving target across jurisdictions, regulatory regimes, and legal timelines. And if your portfolio planning still treats it like a one-size-fits-all calendar event, you’re likely making decisions on incompl…